Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$3.93 +0.3%	$4.16	$1.00 ▼ $5.87	$34.88M	0.8	145,111 shs	66,743 shs
KZR Kezar Life Sciences	$4.44 +4.0%	$4.30	$3.62 ▼ $9.18	$32.44M	0.58	52,690 shs	46,562 shs
MRNS Marinus Pharmaceuticals	$0.55 -0.2%	$0.55	$0.22 ▼ $1.97	$30.32M	1.03	1.82 million shs	260 shs
REXN Rexahn Pharmaceuticals		$2.06	$1.26 ▼ $4.26	$8.11M	0.98	162,968 shs	2,579 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	0.00%	-7.09%	-14.47%	+14.24%	+120.60%
KZR Kezar Life Sciences	0.00%	-1.77%	+6.47%	-9.76%	-29.65%
MRNS Marinus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-56.42%
REXN Rexahn Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	2.6399 of 5 stars	3.3	5.0	0.0	0.0	2.2	1.7	0.0
KZR Kezar Life Sciences	4.4074 of 5 stars	3.2	3.0	0.0	4.6	3.3	2.5	0.6
MRNS Marinus Pharmaceuticals	2.2418 of 5 stars	3.2	0.0	0.0	4.2	0.6	1.7	0.6
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	205.34% Upside
KZR Kezar Life Sciences	2.33	Hold	$39.50	789.64% Upside
MRNS Marinus Pharmaceuticals	2.40	Hold	$3.92	613.29% Upside
REXN Rexahn Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
KZR Kezar Life Sciences	$7M	4.64	N/A	N/A	$16.02 per share	0.28
MRNS Marinus Pharmaceuticals	$30.99M	0.98	N/A	N/A	$0.31 per share	1.77
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	$2.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/4/2025 (Estimated)
KZR Kezar Life Sciences	-$83.74M	-$10.82	N/A	N/A	N/A	N/A	-61.15%	-50.27%	8/12/2025 (Estimated)
MRNS Marinus Pharmaceuticals	-$141.40M	-$2.47	N/A	N/A	N/A	-446.48%	-7,831.35%	-120.74%	8/11/2025 (Estimated)
REXN Rexahn Pharmaceuticals	-$8.64M	N/A	0.00	N/A	N/A	N/A	-72.60%	-55.68%	N/A

Latest REXN, KZR, ATHE, and MRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	KZR Kezar Life Sciences	-$2.56	-$2.27	+$0.29	-$2.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
MRNS Marinus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
KZR Kezar Life Sciences	0.04	7.09	7.09
MRNS Marinus Pharmaceuticals	N/A	1.66	1.47
REXN Rexahn Pharmaceuticals	N/A	3.37	3.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
KZR Kezar Life Sciences	67.90%
MRNS Marinus Pharmaceuticals	98.80%
REXN Rexahn Pharmaceuticals	7.49%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
KZR Kezar Life Sciences	10.40%
MRNS Marinus Pharmaceuticals	5.46%
REXN Rexahn Pharmaceuticals	1.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
KZR Kezar Life Sciences	60	7.31 million	6.55 million	Not Optionable
MRNS Marinus Pharmaceuticals	110	55.22 million	52.20 million	Optionable
REXN Rexahn Pharmaceuticals	5	4.48 million	N/A	Optionable

REXN, KZR, ATHE, and MRNS Headlines

Recent News About These Companies

Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium

August 16, 2024 | br.advfn.com

Aurinia Pharmaceuticals Inc AUPH

February 16, 2024 | morningstar.comM

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

March 27, 2023 | benzinga.com

Rexahn: Holes Galore in Serdaxin Data

January 1, 2023 | thestreet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REXN, KZR, ATHE, and MRNS Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$3.93 +0.01 (+0.26%)

Closing price 06/27/2025 03:57 PM Eastern

Extended Trading

$4.00 +0.06 (+1.65%)

As of 06/27/2025 04:04 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Kezar Life Sciences NASDAQ:KZR

$4.44 +0.17 (+3.98%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.44 0.00 (0.00%)

As of 06/27/2025 04:04 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Marinus Pharmaceuticals NASDAQ:MRNS

$0.55 0.00 (-0.16%)

As of 02/11/2025

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Rexahn Pharmaceuticals NASDAQ:REXN

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time